X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DOPTELET® (avatrombopag maleate), an oral thrombopoietin receptor agonist, which is indicated for the of thrombocytopenia and for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.
Lead Product(s): Avatrombopag Maleate
Therapeutic Area: Immunology Product Name: Doptelet
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
Sobi will transition the manufacturing and development rights of ImmTOR for SEL-212 to Sobi. SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is in development for chronic refractory gout.
Lead Product(s): Pegadricase,ImmTOR
Therapeutic Area: Rheumatology Product Name: SEL-212
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Selecta Biosciences
Deal Size: $705.0 million Upfront Cash: $75.0 million
Deal Type: Licensing Agreement October 31, 2023
Details:
The acquisition strengthens Sobi’s leading haematology franchise by adding Vonjo (pacritinib), a novel oral kinase inhibitor that inhibits JAK2, IRAK1 and ACRV1, while sparing JAK1, for the treatment of adults with myelofibrosis. Vonjo obtained accelerated approval by the FDA.
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: Vonjo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: CTI BioPharma Corp
Deal Size: $1,700.0 million Upfront Cash: $1,700.0 million
Deal Type: Acquisition June 26, 2023
Details:
Syfovre™ (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). It targets C3 to provide comprehensive control of the complement cascade, part of the body’s immune system.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Neurology Product Name: Syfovre
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: Apellis Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
Altuviiio (efanesoctocog alfa) is a novel and investigational recombinant factor VIII therapy with the potential to deliver near-normal factor activity levels, extending bleed protection in a once-weekly dose for people with haemophilia A.
Lead Product(s): Efanesoctocog Alfa
Therapeutic Area: Genetic Disease Product Name: Altuviiio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2023
Details:
The acquisition will diversify Sobi's portfolio of leading hematology medicines through CTI's lead product, VONJO® (pacritinib), which is FDA-approved for the treatment of adult myelofibrosis patients with a platelet count below 50 x109/L.
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: Vonjo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: CTI BioPharma Corp
Deal Size: $1,700.0 million Upfront Cash: $1,700.0 million
Deal Type: Acquisition May 10, 2023
Details:
The termination removes Sobi's right to AstraZeneca's full share of US profits and losses for Beyfortus (nirsevimab), a long-acting intramuscular recombinant neutralising human IgG1ĸ monoclonal antibody, including US development and commercialisation costs.
Lead Product(s): Nirsevimab
Therapeutic Area: Infections and Infectious Diseases Product Name: Beyfortus
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: AstraZeneca
Deal Size: Undisclosed Upfront Cash: $15.0 million
Deal Type: Termination April 10, 2023
Details:
The termination removes Sobi's right to AstraZeneca's full share of US profits and losses for Beyfortus (nirsevimab), a long-acting intramuscular recombinant neutralising human IgG1ĸ monoclonal antibody, including US development and commercialisation costs.
Lead Product(s): Nirsevimab
Therapeutic Area: Infections and Infectious Diseases Product Name: Beyfortus
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 09, 2023
Details:
Gamifant (emapalumab-lzsg) is a fully human, anti-IFNγ mAb that binds free and receptor-bound IFNγ, neutralizing its biological activity. In the US, it is indicated for pediatric and adult primary hemophagocytic lymphohistiocytosis (HLH) patients.
Lead Product(s): Emapalumab-lzsg
Therapeutic Area: Immunology Product Name: Gamifant
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
Altuviiio (efanesoctocog alfa) is a novel and investigational recombinant factor VIII therapy with the potential to deliver near-normal factor activity levels for most of the week, extending bleed protection in a once-weekly dose for people with haemophilia A.
Lead Product(s): Efanesoctocog Alfa
Therapeutic Area: Genetic Disease Product Name: Altuviiio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
